Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid

Pacira BioSciences' (PCRX) shares plunged 47.7% on Aug 9, after the U.S. District Court for the District of New Jersey ruled that the company's '495 patent for Exparel (bupivacaine liposome injectable suspension) is not valid. An invalid patent means that the non-opioid pain management market would be flooded by generic versions of Pacira's lead drug Exparel once it loses exclusivity, which will eat away from the drug's commercial opportunity. Please note that the company's flagship product, Exparel, launch ...